Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other Events

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Files An 8-K Other Events
Item 8.01Other Events.

Story continues below

Effective as of February 7, 2019, Brett Fair, the Chief Commercial Officer of Aclaris Therapeutics, Inc. (the “Company”), is no longer employed by the Company.

About Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK). It has completed approximately three Phase II clinical trials of A-101. It has initiated over two multi-center, double blind Phase III clinical trials and an open label Phase III clinical trial of A-101 in patients with SK. It also intends to develop A-101 as a prescription treatment for common warts, also known as verruca vulgaris, and A-102, a gel dosage form of hydrogen peroxide, as a prescription treatment for SK and common warts. It has initiated a Phase II clinical trial to evaluate A-101 for the treatment of common warts.

An ad to help with our costs